Company
biotech giant
Every investor coverage indicates participated in a round Roche Group raised.
Companies Roche Group acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Steve Burnell | Executive (former) | Business News Australia, Brandon Capital portfolio, Brandon BioCatalyst portfolio |
Stories naming Roche Group. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Biotech Aravax has received a US$20 million Series B commitment from Brandon Capital and Tenmile to advance its peanut allergy therapy PVX108 into Phase 2 trials.
Also Brandon Capital portfolio·Startup Daily·Startup News (WA)·Techboard·Startup Daily